title: [Staphylokinase for a better thrombolytic treatment of heart and platelet diseases].
abstract: Staphylokinase is a plasminogen activator of bacterial origin with pronounced fibrin specificity. The first clinical studies suggest that recombinant staphylokinase (Sak) constitutes an effective thrombolytic agent in the treatment of patients with myocardial infarction or peripheral arterial occlusion. Also in an animal ischemic stroke model Sak has produced promising results. Despite its fibrin specificity life-threatening bleeding still may occur. Sak induces neutralizing antibodies that may interfere with renewed administration. Therefore, recombinant variants have been engineered that are less antigenic while preserving thrombolytic properties.
authors.affiliation: Algemeen Inwendige Geneeskunde en Centrum voor Moleculaire en Vasculaire Biologie, Faculteit Geneeskunde, U.Z. Gasthuisberg, Leuven.
authors.forename: S
authors.initials: S
authors.lastname: Vanderschueren
mesh_terms: D000818:Animals; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005818:Genetic Engineering; D006801:Humans; D008666:Metalloendopeptidases / Q000235:genetics / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy*; D010960:Plasminogen Activators / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010960:Plasminogen Activators; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus